Cumberland Pharmaceuticals CPIX Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Acetadote | $408.79K+59.3% | $508.46K+175% | $482K+195% | $406.78K+55.1% | $256.63K-30.5% | |
| Caldolor | $4.32M-10.0% | $4.66M-6.0% | $5.14M+11.6% | $5.54M+23.5% | $4.8M-1.5% | |
| Kristalose | $8.04M-48.5% | $10.54M-31.2% | $11.8M-19.2% | $14.25M-4.1% | $15.6M+5.0% | |
| Other revenue | $1.15M-72.5% | $4.13M+210% | $4.16M— | $4.48M— | $4.2M— | |
| Sancuso | $12.58M+33.3% | $11.91M+32.2% | $11M+22.4% | $10.36M+24.7% | $9.43M+17.4% | |
| Vibativ | $10.23M+19.5% | $11.11M+55.1% | $10.37M+45.8% | $8.8M-0.8% | $8.55M-0.2% | |
| Non-current inventories by Product | ||||||
| Acetadote | $116.91K+5.1% | $120.88K+10.8% | $120.64K+41.6% | $82.54K— | $111.19K— | |
| Caldolor | $489.01K+19.8% | $572K+102% | $536.62K+96.4% | $472.71K— | $408.1K— | |
| Ifetroban | $212.3K-70.7% | $321.82K— | $447.87K— | $585.98K— | $724.09K— | |
| Kristalose | $9.46M-12.3% | $9.62M-16.9% | $10.03M-17.5% | $10.52M— | $10.79M— | |
| Sancuso | $1.88M-6.1% | $1.65M-24.9% | $1.45M-37.2% | $1.8M— | $2.01M— | |
| Vaprisol | $4.69M-0.1% | $4.69M— | $4.69M— | $4.69M— | $4.69M— | |
| Vibativ | $20.14M-18.0% | $19.94M-22.7% | $21.23M-19.1% | $22.75M— | $24.55M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Cumberland Pharmaceuticals break its business down?
- Cumberland Pharmaceuticals (CPIX) reports revenue by product across 7 parts — Acetadote, Caldolor, Kristalose, Other revenue and Sancuso. Each is extracted from the segment footnotes and tracked over time.
- Where does Cumberland Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Cumberland Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
